Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amitriptyline/oxymetazoline/ketoprofen - Omeros Corporation

Next Previous
Drug Profile

Amitriptyline/oxymetazoline/ketoprofen - Omeros Corporation

Alternative Names: Ketoprofen/amitriptyline/oxymetazoline; Ketoprofen/oxymetazoline/amitriptyline; OMS 103; OMS-103-HP; Oxymetazoline/amitriptyline/ketoprofen

Latest Information Update: 27 Aug 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Omeros Corporation
  • Class Dibenzocycloheptenes; Imidazoles; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Lipoxygenase-cyclooxygenase inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postoperative pain

Most Recent Events

  • 29 Apr 2019 Omeros Corporation has patent protection for amitriptyline/oxymetazoline/ketoprofen in USA and other undisclosed countries
  • 29 Apr 2019 Omeros Corporation has patents pending for amitriptyline/oxymetazoline/ketoprofen in USA and other undisclosed countries
  • 08 Nov 2018 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top